Background
==========

Early innate human defenses against microbial invaders include mannose-binding lectin (MBL), a serum protein, which acts as a microbial opsonin and initiates activation of the so-called lectin complement activation pathway. Deficiencies in innate immunity have been hypothesized to allow chronic inflammatory states that may contribute to the pathogenesis of atherosclerosis \[[@B1]\]. Common variations in the MBL gene (*MBL2*), between 12 to 25% allele frequencies in Caucasian and other populations \[[@B2]\], result in markedly **lower**levels of circulating MBL \[[@B3]\] and are associated with both an increased susceptibility to infections \[[@B4]\] and cardiovascular disease in many \[[@B5]-[@B8]\], but not all studies \[[@B9]\]. An independent association between variant *MBL2*genotypes and coronary artery disease (CAD) was previously confirmed in the American Indian, Strong Heart Study (SHS) cohort (OR = 3.2, 95% CI 1.5--7.0, p = 0.004, adjusted for 11 CAD covariates) \[[@B10]\]. On the other hand, genetypes resulting in **high**levels of MBL may be involved in complications related to cardiovascular disease (CVD). Thus, the role of MBL in cardiovascular disease appears to be a double-edged sword, due to hitherto only partially resolved mechanisms \[[@B11]-[@B13]\].

Although considerable effort has focused on the genotypic determination of MBL levels, our understanding of the role of various promoters and structural genetic variations remains incomplete. New promoter variants continue to be identified \[[@B14],[@B15]\] and genetic background effects in specific populations are largely unknown.

MBL is also known to increase during an acute-phase reaction \[[@B16]\]. Samples collected during follow-up of a subset of the SHS cohort provide a valuable opportunity to test the correlation of both genotype and environmental exposures (e.g. incident CAD and inflammation, as measured by C-reactive protein (CRP) or fibrinogen) with MBL levels in this population.

Methods
=======

The previously mentioned SHS case/control study matched cases and controls on age, gender and recruitment center (Arizona (AZ), Dakotas (DK) and Oklahoma (OK)). From this group a subset was chosen to include 186 of the controls without regard to genotype and an additional 51 cases limited to those known to be homozygous for high expressing \"HYA\" alleles.

Ascertainment of fatal and nonfatal cardiovascular events occurring between examinations was accomplished by medical record review and/or yearly participant contact \[[@B17]\]. Cases were defined by evidence of definite myocardial infarction (MI), definite coronary artery disease (CAD) without MI, definite evidence of MI by Minnesota ECG coding \[[@B17]\], or mortality codes indicating either definite MI, sudden death due to CAD, or definite coronary heart disease occurring between 5/18/89 and 12/31/99 \[[@B18]\]. Participants with only a diagnosis of possible CAD, \"other CAD\", stroke, congestive heart failure, or peripheral vascular disease were excluded. Controls were those individuals without any of the above diagnoses. MBL levels, *MBL2*genotypes and other covariates were determined from both of these groups. American Diabetes Association criteria \[[@B19]\] were used to classify participant diabetic status in table [1](#T1){ref-type="table"}. Participants were considered hypertensive if they were taking anti-hypertensive medications, had a systolic blood pressure greater than 140 mm Hg, or a diastolic blood pressure greater than 90 mm Hg.

###### 

Characteristics of cases and controls analyzed.

  ---------------------------------------------------------------------------------
  Characteristic                                               Cases\   Controls\
                                                               N = 51   N = 186
  ------------------------------------------------------------ -------- -----------
  Gender (% Female)                                            49       52

                                                                        

  Age (years)                                                  60.1     58.7

                                                                        

  Percentage of participants reporting 100% AI heritage        78       68

                                                                        

  Median percent AI heritage among those with less than 100%   65.6     50

                                                                        

  Diabetes Mellitus (%)                                        64.7     39.8

                                                                        

  Hypertension (%)                                             27.5     22.6

                                                                        

  Smoking, current (%)                                         37.3     25.3

                                                                        

  Alcohol, current use (%)                                     41       36

                                                                        

  Weight (Kg)                                                  82.9     84.2

                                                                        

  BMI (Kg/m^2^)                                                29.4     30.4

                                                                        

  Hgb A1c (%)                                                  8.2      6.4

                                                                        

  LDL Cholesterol (mg/dl)                                      130.2    119.1

                                                                        

  Triglycerides (mg/dl)                                        198.1    125.5

                                                                        

  CRP (mg/dl)                                                  2.99     3.45

                                                                        

  Fibrinogen (mg/dl)                                           319.8    304.7

                                                                        

  PAI-1 (mg/dl)                                                43.3     46.8
  ---------------------------------------------------------------------------------

Determination of MBL levels was done at Rigshositalet in Copenhagen, Denmark, using a double sandwich ELISA method as previously described \[[@B20]\].

The *MBL2*gene was assessed for the presence of the B (G54D), C (G57E) or D (R52C) structural variations, and two promoter polymorphisms, one a G/C transition at -550 bp (the H/L alleles) \[[@B21]\] and the other, a G/C transition at -221 (X/Y alleles). These structural variations have typically been labeled \"O\" alleles in contrast to the most common \"A\" allele. Genotypes were determined by the oligonucleotide ligation assay as described by Nickerson and colleagues \[[@B22]\]. Quality control, duplicate, genotyping was performed by direct DNA sequencing. The structural variations were assumed to occur on opposing chromosomes. A number of promoter variants and structural alleles have been found to be in complete linkage disequilibrium and genotypes were checked against these established relationships. \[[@B23]\]. Genotyping was conducted at the University of Pittsburgh, Pittsburgh, Pennsylvania.

Composite categories of genotypes predicted to result in reduced expression of *MBL2*similar to previous reports \[[@B3]\], primarily A_A, A_O, O_O, YA_O, XA_O, HA_O, LA_O, HYA_O, LYA_O, LXA_O, along with selected specific haplotypes of adequate prevalence, were used to guide analysis of genotypic effects on MBL levels. More inclusive categories used in the previous SHS *MBL2*analysis \[[@B10]\] were also considered. Low expression of *MBL2*(LOW_1) was assumed from the presence of an O_O or LA_O genotype. The LOW_2 category consisted of either O_O, LA_O or LA_LA genotypes. These risk categories were compared with reference groups ALL_1 or ALL_2, consisting of all genotypes not included in either LOW_1 or LOW_2 respectively; or the HIGH category (either HA_HA or HA_LA). There is ample documentation of the biologic effect of these various genotypes on basal MBL levels \[[@B23]\], although unidentified background genetic influences in unique populations are of interest.

The Chi square statistic was used to evaluate proportions between groups. Multivariate regression models and comparison of means (t test of independent samples) were used to understand the contribution of the various factors to *MBL2*expression using SPSS version 10.1.0 software. The distributions of all subgroups in table [2](#T2){ref-type="table"} were examined and no deviation from the normal distribution was detected. A nominal p value of 0.05 was used to determine statistical significance and the Bonferroni correction was applied in situations of multiple testing.

###### 

MBL levels (μg/L) found in various genotypes and genotypic categories.

  Haplotype     N     Min    Max    Mean     SD
  ------------- ----- ------ ------ -------- --------
  Controls                                   
                                             
  HYA_HYA       76    128    3920   1863.2   854.95
                                             
  HYA_LYA       34    400    3296   1422.6   826.14
                                             
  HYA_LXA       21    223    2848   1030.8   709.6
                                             
  LYA_LYA       2     1040   3024   2032.0   1402.9
                                             
  LYA_LXA       1                   1376.0   
                                             
  LXA_LXA       1                   3616.0   
                                             
  HYA_B         27    0      768    168.9    150.7
                                             
  HYA_C         1                   273.0    
                                             
  HYA_D         7     157    1840   696.29   585.9
                                             
  LYA_B         8     24     233    115.25   84.1
                                             
  LYA_D         1                   448.0    
                                             
  LXA_B         1                   0.0      
                                             
  B_B           6     0      0      0.0      
                                             
  YA_O          44    0      1840   251.7    321.9
                                             
  XA_O          1                   0.0      
                                             
  XA_O or O_O   7     0      0      0.0      
                                             
  HA_HA         76    128    3920   1863.2   854.9
                                             
  HA_LA         55    223    3296   1273.0   800.3
                                             
  LA_LA         4     1040   3616   2264.0   1250.6
                                             
  HA_O          35    0      1840   277.3    351.3
                                             
  LA_O          10    0      448    137.0    137.0
                                             
  HIGH          131   128    3920   1615.4   879.3
                                             
  **LOW_1**     16    0      448    85.6     126.3
                                             
  **LOW_2**     20    0      3616   521.3    1029.0
                                             
  A_A           135   128    3920   1634.7   893.0
                                             
  Not \"A_A\"   51    0      1840   217.2    311.1
                                             
  Cases                                      
                                             
  HYA_HYA       51    640    5888   1903.6   1043.4

Approval consistent with the Helsinki Declaration was obtained from all relevant Institutional Review Boards and tribes, and all participants gave informed consent.

Results
=======

Table [1](#T1){ref-type="table"} summarizes the characteristics of both cases and controls. Please note that cases for this study were chosen on the basis of genotype and since cases and controls were initially matched for gender, age, and recruitment center, comparison between aggregated case and control samples should be interpreted with caution.

There were no significant differences in the prevalence of O (15.3%) and H (67.2%) alleles in this control sample, compared with an earlier SHS report \[[@B10]\].

These findings confirm low levels of MBL among individuals with composite genotypic groups (eg O_O, XA_O, LA_O) \[[@B2]\], as well as those previously associated with CAD in this SHS population (bolded) \[[@B10]\], as seen in table [2](#T2){ref-type="table"}.

Among controls only, comparing means of composite genotypes showed highly significant differences (p \< 0.001 for all comparisons) between either the HYA_HYA or HIGH groups and any of the YA_O, HA_O, LA_O, O_O, LOW1, or LOW2 groups. Figure [1](#F1){ref-type="fig"} shows these comparisons in the familiar \"box-plot\" format. The difference in mean MBL between HYA_HYA and HYA_LYA (unadjusted for multiple testing, p \< 0.013), was not significant considering a Bonferroni correction requiring a p \< 0.00365 for a total of 14 pair-wise tests. No significant differences were found between MBL means of HYA_LYA and HYA_LXA or HYA_B and LYA_B (although the last category was represented by only 8 individuals); other comparisons attempting to isolate the influence of the H/L or X/Y promoters were not possible due to small numbers of individuals in categories.

![**MBL levels for various genotypes**. Comparison of mean HIGH and HYA_HYA MBL levels with all other groups is significant at p \< 0.001. Outliers (between 1.5 and 3 box lengths from upper and lower margin) and extreme values (greater than 3 box lengths from box margin) are denoted by \"o\" and \"**\***\" respectively.](1471-2350-10-5-1){#F1}

Only cases with HYA_HYA genotype were included to allow adequate numbers to compare with controls of identical genotype. If the mean MBL levels for case and control groups of identical genotype are compared (ignoring the previously matched selection of cases and controls on the basis of age, gender and center), then a crude p value of 0.812 is obtained.

Multivariate regression analysis was used to investigate the interplay of various demographic, environmental, genetic factors on expression of *MBL2*within the control group. A backward selection criterion of F ≥ 0.1 was used and results are summarized in table [3](#T3){ref-type="table"}. Male gender, hemoglobin A1c levels and self-reported % American Indian ethnicity are positively correlated with MBL levels; whereas the converse is true of increasing triglyceride levels and the number of B alleles. Covariates not retained in this backward selection included: age, diabetes mellitus, systolic blood pressure, Chlamydia pneumoniae (Cp) antibody titers, percent body fat, and urinary albumin/creatinine ratio. Although MBL is an acute phase reactant, it was not correlated with either inflammatory measures (CRP, PAI-1, fibrinogen, WBC count) or infectious disease exposure (Cp titers).

###### 

Results of multivariate regression analysis on the control group (n = 186).

  Factor                         beta coefficient   p value
  ------------------------------ ------------------ ---------
  MALE GENDER                    .161               .011
                                                    
  \% AMERICAN INDIAN ETHNICITY   .216               .001
                                                    
  ln TRIGLYCERIDES               -.159              .013
                                                    
  HEMOGLOBIN A1c                 .219               .001

Discussion
==========

Genetic variation in the *MBL2*gene has been implicated in important pathophysiologic processes including susceptibility to infections \[[@B24]-[@B26]\], chronic inflammatory states and their sequelae \[[@B5],[@B6],[@B8],[@B27]\], and the response to acute pathology, such as ischemic necrosis \[[@B28]\]. Further down the pathogenetic chain of events, circulating levels of this protein are also associated with pathology \[[@B27],[@B29],[@B30]\]. It is therefore important to fully understand the genetic and environmental factors governing expression of this protein. Since MBL is a polymeric protein comprised of self-assembled trimeric subunits, dominant-negative structural variants were first recognized to have marked effects on functional MBL levels. Promoter polymorphisms were soon recognized as key determinants of *MBL2*expression and as recently as 2006, new variants have been identified \[[@B3],[@B15],[@B31]\]. It is likely that additional influences (eg the endocrine milleu \[[@B32],[@B33]\], variation in multimeric assembly \[[@B34]\], and epigenetic effects determined by the \"background\" population \[[@B3]\] on *MBL2*expression and function will continue to be uncovered. The worldwide high population prevalence of these variants suggests an apparently ambivalent role of *MBL2*in a number of pathogenetic and homeostatic processes \[[@B35]-[@B37]\].

In this report we have generally confirmed the previously reported influence of the three main structural variants and the two most widely investigated promoter variants (H/L and X/Y). This is of importance due to the demonstrated association between CVD and these variants in this particular, non-Caucasian population. Other studies have reported on the prevalence of *MBL2*variants in native populations of North America \[[@B38]\]; but have not included information on the expression of *MBL2*, as in the present study. Since MBL levels are higher in those with diabetes (although not seen in this dataset) \[[@B27]\], a correlation with HgbA1c could be expected. The finding of an association with lower levels of triglycerides in adjusted analysis is more difficult to explain, especially since triglyceride levels are often increased in those with diabetes or the metabolic syndrome \[[@B39]\]. Others have also reported increased MBL levels among males \[[@B30]\]; but no previous analyses of triglycerides in relation to MBL could be found in the literature.

Strengths of this study include confirmation of the presumed link between genotype and expressed protein, increasing confidence in a possibly causal association between MBL and cardiovascular disease in this population. These results also extend the previously identified genotype/phenotype correlations to another population with a unique genetic background. A weakness is the previous matching structure of the sample and the need to compare HYA/HYA case genotypes with the same control genotypes. There were an insufficient number of previously matched pairs with this genotype to allow a matched analysis, thus the aggregate comparison between these two groups needs to be interpreted with caution.

Conclusion
==========

The findings from our study corroborate previous research that has demonstrated the important effects of genetic variants and the association of metabolic abberations with MBL levels. Further understanding of *MBL2*expression may improve our ability to understand and disrupt the pathogenetic mechanisms involved in cardiovascular disease.
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